Development of a dosing-adjustment tool for fluoroquinolones in osteoarticular infections: The Fluo-pop study

Fluoroquinolones efficacy depend on both the drug exposure and the level of drug resistance of the bacteria responsible for the infection. Specifically for the Staphylococcus species, which is the microorganism mainly involved in osteoarticular infections (OAI), in-vitro data reported that an AUC/MI...

Full description

Bibliographic Details
Main Authors: Florian Lemaitre, Fabien Fily, Jean-Baptiste Foulquier, Matthieu Revest, Vincent Jullien, Antoine Petitcollin, Pierre Tattevin, Camille Tron, Jean-Louis Polard, Marie-Clémence Verdier, Emmanuelle Comets, Denis Huten, Cédric Arvieux, Eric Bellissant, Bruno Laviolle
Format: Article
Language:English
Published: Elsevier 2021-10-01
Series:Biomedicine & Pharmacotherapy
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S0753332221008362
id doaj-d54980683e2340cfbd3b76108f868123
record_format Article
collection DOAJ
language English
format Article
sources DOAJ
author Florian Lemaitre
Fabien Fily
Jean-Baptiste Foulquier
Matthieu Revest
Vincent Jullien
Antoine Petitcollin
Pierre Tattevin
Camille Tron
Jean-Louis Polard
Marie-Clémence Verdier
Emmanuelle Comets
Denis Huten
Cédric Arvieux
Eric Bellissant
Bruno Laviolle
spellingShingle Florian Lemaitre
Fabien Fily
Jean-Baptiste Foulquier
Matthieu Revest
Vincent Jullien
Antoine Petitcollin
Pierre Tattevin
Camille Tron
Jean-Louis Polard
Marie-Clémence Verdier
Emmanuelle Comets
Denis Huten
Cédric Arvieux
Eric Bellissant
Bruno Laviolle
Development of a dosing-adjustment tool for fluoroquinolones in osteoarticular infections: The Fluo-pop study
Biomedicine & Pharmacotherapy
Ofloxacin
Pharmacokinetics
Bone infection
Joint infection
Modeling
author_facet Florian Lemaitre
Fabien Fily
Jean-Baptiste Foulquier
Matthieu Revest
Vincent Jullien
Antoine Petitcollin
Pierre Tattevin
Camille Tron
Jean-Louis Polard
Marie-Clémence Verdier
Emmanuelle Comets
Denis Huten
Cédric Arvieux
Eric Bellissant
Bruno Laviolle
author_sort Florian Lemaitre
title Development of a dosing-adjustment tool for fluoroquinolones in osteoarticular infections: The Fluo-pop study
title_short Development of a dosing-adjustment tool for fluoroquinolones in osteoarticular infections: The Fluo-pop study
title_full Development of a dosing-adjustment tool for fluoroquinolones in osteoarticular infections: The Fluo-pop study
title_fullStr Development of a dosing-adjustment tool for fluoroquinolones in osteoarticular infections: The Fluo-pop study
title_full_unstemmed Development of a dosing-adjustment tool for fluoroquinolones in osteoarticular infections: The Fluo-pop study
title_sort development of a dosing-adjustment tool for fluoroquinolones in osteoarticular infections: the fluo-pop study
publisher Elsevier
series Biomedicine & Pharmacotherapy
issn 0753-3322
publishDate 2021-10-01
description Fluoroquinolones efficacy depend on both the drug exposure and the level of drug resistance of the bacteria responsible for the infection. Specifically for the Staphylococcus species, which is the microorganism mainly involved in osteoarticular infections (OAI), in-vitro data reported that an AUC/MIC ratio above 115 h maximizes drug efficacy. However, data on OAI patients are lacking and a simple approach to access AUCs is still a clinical issue. We conducted a prospective, single-center study in 30 OAI patients hospitalized in the Rennes University Hospital to model ofloxacin pharmacokinetics and to define a limited sampling strategy (LSS) suitable for ofloxacin and levofloxacin treatments. Modeling was conducted with the Monolix software. The final model was externally validated using levofloxacin data. Monte-Carlo simulations were used to evaluate the probability of target attainment (PTA) of different dosing regimens. Two hundred and ninety-seven (297) ofloxacin concentrations were available for the pharmacokinetic modeling. Ofloxacin pharmacokinetics was best described using a bicompartmental model with a first order elimination, and a transit compartment model absorption. CKD-EPI and sex explained half of ofloxacin pharmacokinetic variability. For LSS, the 0, 1 h and 3 h sampling scheme resulted in the best approach both for BID and TID dosages (R2 adjusted = 91.1% and 95.0%, outliers = 4.8% and 5.0%, respectively). PTA allows choosing the best drug and dosage according to various hypotheses. A simple 3-sample protocol (pre-dose, 1 h after intake and 3 h after intake) to estimate ofloxacin and levofloxacin AUC allows optimal drug dosage for the treatment of osteoarticular infections.
topic Ofloxacin
Pharmacokinetics
Bone infection
Joint infection
Modeling
url http://www.sciencedirect.com/science/article/pii/S0753332221008362
work_keys_str_mv AT florianlemaitre developmentofadosingadjustmenttoolforfluoroquinolonesinosteoarticularinfectionsthefluopopstudy
AT fabienfily developmentofadosingadjustmenttoolforfluoroquinolonesinosteoarticularinfectionsthefluopopstudy
AT jeanbaptistefoulquier developmentofadosingadjustmenttoolforfluoroquinolonesinosteoarticularinfectionsthefluopopstudy
AT matthieurevest developmentofadosingadjustmenttoolforfluoroquinolonesinosteoarticularinfectionsthefluopopstudy
AT vincentjullien developmentofadosingadjustmenttoolforfluoroquinolonesinosteoarticularinfectionsthefluopopstudy
AT antoinepetitcollin developmentofadosingadjustmenttoolforfluoroquinolonesinosteoarticularinfectionsthefluopopstudy
AT pierretattevin developmentofadosingadjustmenttoolforfluoroquinolonesinosteoarticularinfectionsthefluopopstudy
AT camilletron developmentofadosingadjustmenttoolforfluoroquinolonesinosteoarticularinfectionsthefluopopstudy
AT jeanlouispolard developmentofadosingadjustmenttoolforfluoroquinolonesinosteoarticularinfectionsthefluopopstudy
AT marieclemenceverdier developmentofadosingadjustmenttoolforfluoroquinolonesinosteoarticularinfectionsthefluopopstudy
AT emmanuellecomets developmentofadosingadjustmenttoolforfluoroquinolonesinosteoarticularinfectionsthefluopopstudy
AT denishuten developmentofadosingadjustmenttoolforfluoroquinolonesinosteoarticularinfectionsthefluopopstudy
AT cedricarvieux developmentofadosingadjustmenttoolforfluoroquinolonesinosteoarticularinfectionsthefluopopstudy
AT ericbellissant developmentofadosingadjustmenttoolforfluoroquinolonesinosteoarticularinfectionsthefluopopstudy
AT brunolaviolle developmentofadosingadjustmenttoolforfluoroquinolonesinosteoarticularinfectionsthefluopopstudy
_version_ 1717376423962869760
spelling doaj-d54980683e2340cfbd3b76108f8681232021-09-19T04:54:33ZengElsevierBiomedicine & Pharmacotherapy0753-33222021-10-01142112053Development of a dosing-adjustment tool for fluoroquinolones in osteoarticular infections: The Fluo-pop studyFlorian Lemaitre0Fabien Fily1Jean-Baptiste Foulquier2Matthieu Revest3Vincent Jullien4Antoine Petitcollin5Pierre Tattevin6Camille Tron7Jean-Louis Polard8Marie-Clémence Verdier9Emmanuelle Comets10Denis Huten11Cédric Arvieux12Eric Bellissant13Bruno Laviolle14Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, F-35000 Rennes, France; INSERM, Centre d’Investigation Clinique, CIC 1414, F-35000 Rennes, France; Correspondence to: Department of Pharmacology, Rennes University Hospital, 2, rue Henri Le Guilloux CEDEX, 35033 Rennes, France.Epicentre, 55 rue Crozatier, 75012, Paris, France; Infectious Diseases Unit, Broussais Hospital, Saint Malo, FranceUniv Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, F-35000 Rennes, France; INSERM, Centre d’Investigation Clinique, CIC 1414, F-35000 Rennes, FranceINSERM, Centre d’Investigation Clinique, CIC 1414, F-35000 Rennes, France; Infectious Diseases and Intensive Care Unit, Pontchaillou University Hospital, Rennes, France; University of Rennes, Inserm, BRM (Bacterial Regulatory RNAs and Medicine), UMR, FranceUniversity Paris 13, groupe hospitalier Paris Seine-Saint-Denis, Assistance publique-Hôpitaux de Paris, 93000 Bobigny, France; Molecular Mycology Unit-CNRS UMR 2000, Pasteur Institute, 75015 Paris, FranceINSERM, Centre d’Investigation Clinique, CIC 1414, F-35000 Rennes, FranceINSERM, Centre d’Investigation Clinique, CIC 1414, F-35000 Rennes, France; Infectious Diseases and Intensive Care Unit, Pontchaillou University Hospital, Rennes, France; University of Rennes, Inserm, BRM (Bacterial Regulatory RNAs and Medicine), UMR, FranceUniv Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, F-35000 Rennes, France; INSERM, Centre d’Investigation Clinique, CIC 1414, F-35000 Rennes, FranceDepartment of Orthopaedic Surgery and Traumatology, Pontchaillou University Hospital, 2 Avenue Henri Le Guilloux, 35203 Rennes, FranceUniv Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, F-35000 Rennes, France; INSERM, Centre d’Investigation Clinique, CIC 1414, F-35000 Rennes, FranceUniv Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, F-35000 Rennes, France; INSERM, Centre d’Investigation Clinique, CIC 1414, F-35000 Rennes, FranceDepartment of Orthopaedic Surgery and Traumatology, Pontchaillou University Hospital, 2 Avenue Henri Le Guilloux, 35203 Rennes, FranceInfectious Diseases and Intensive Care Unit, Pontchaillou University Hospital, Rennes, France; University of Rennes, Inserm, BRM (Bacterial Regulatory RNAs and Medicine), UMR, France; Great West Reference centers for Complex Bone and Joint Infections (CRIOGO), FranceUniv Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, F-35000 Rennes, France; INSERM, Centre d’Investigation Clinique, CIC 1414, F-35000 Rennes, FranceUniv Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, F-35000 Rennes, France; INSERM, Centre d’Investigation Clinique, CIC 1414, F-35000 Rennes, FranceFluoroquinolones efficacy depend on both the drug exposure and the level of drug resistance of the bacteria responsible for the infection. Specifically for the Staphylococcus species, which is the microorganism mainly involved in osteoarticular infections (OAI), in-vitro data reported that an AUC/MIC ratio above 115 h maximizes drug efficacy. However, data on OAI patients are lacking and a simple approach to access AUCs is still a clinical issue. We conducted a prospective, single-center study in 30 OAI patients hospitalized in the Rennes University Hospital to model ofloxacin pharmacokinetics and to define a limited sampling strategy (LSS) suitable for ofloxacin and levofloxacin treatments. Modeling was conducted with the Monolix software. The final model was externally validated using levofloxacin data. Monte-Carlo simulations were used to evaluate the probability of target attainment (PTA) of different dosing regimens. Two hundred and ninety-seven (297) ofloxacin concentrations were available for the pharmacokinetic modeling. Ofloxacin pharmacokinetics was best described using a bicompartmental model with a first order elimination, and a transit compartment model absorption. CKD-EPI and sex explained half of ofloxacin pharmacokinetic variability. For LSS, the 0, 1 h and 3 h sampling scheme resulted in the best approach both for BID and TID dosages (R2 adjusted = 91.1% and 95.0%, outliers = 4.8% and 5.0%, respectively). PTA allows choosing the best drug and dosage according to various hypotheses. A simple 3-sample protocol (pre-dose, 1 h after intake and 3 h after intake) to estimate ofloxacin and levofloxacin AUC allows optimal drug dosage for the treatment of osteoarticular infections.http://www.sciencedirect.com/science/article/pii/S0753332221008362OfloxacinPharmacokineticsBone infectionJoint infectionModeling